Literature DB >> 23411600

HEART score to further risk stratify patients with low TIMI scores.

Shannon Marcoon1, Anna Marie Chang, Betsy Lee, Rama Salhi, Judd E Hollander.   

Abstract

OBJECTIVE: The ability to risk stratify patients presenting to the emergency department (ED) with potential acute coronary syndrome (ACS) is critical. The thrombolysis in myocardial infarction (TIMI) risk score can risk stratify ED patients with potential ACS but cannot identify patients safe for ED discharge. The symptom-based HEART score identifies very low-risk patients. Our hypothesis was that patients with a TIMI score of 0 or 1 may be stratified further with the HEART score to identify a group of patients at less than 1% risk of 30-day cardiovascular events.
METHODS: We conducted a secondary analysis of a prospective cohort study in a tertiary care hospital ED. Patients with potential ACS who were >30 years of age were included. Data collected included demographics, history, electrocardiogram, laboratories, and components of the TIMI and HEART scores. Follow-up was conducted by structured record review and phone. The main outcome was a composite of death, acute myocardial infarction, or revascularization at 30 days.
RESULTS: There were 8815 patients enrolled (mean age, 52.8 ± 15.1 years; 57% women, and 69% black). At 30 days, the composite event rate was 8.0% (660 patients): 108 deaths, 410 acute myocardial infarction, and 301 revascularizations. Of the 485 patients with both a TIMI score of 0 and a HEART score of 0, there were no cardiovascular events (95% confidence interval, 0-0.8%); but no other score combination had an upper limit confidence interval less than 1%.
CONCLUSION: At all levels of TIMI score, the HEART score was able to further substratify patients with respect to 30-day risk. A HEART score of 0 in a patient with a TIMI of 0 identified a group of patients at less than 1% risk for 30-day adverse events.

Entities:  

Mesh:

Year:  2013        PMID: 23411600     DOI: 10.1097/HPC.0b013e31827377e1

Source DB:  PubMed          Journal:  Crit Pathw Cardiol        ISSN: 1535-2811


  6 in total

Review 1.  Shared Decision-Making as the Future of Emergency Cardiology.

Authors:  Marc A Probst; Peter A Noseworthy; Juan P Brito; Erik P Hess
Journal:  Can J Cardiol       Date:  2017-09-22       Impact factor: 5.223

2.  Identification of Emergency Department Patients With Acute Heart Failure at Low Risk for 30-Day Adverse Events: The STRATIFY Decision Tool.

Authors:  Sean P Collins; Cathy A Jenkins; Frank E Harrell; Dandan Liu; Karen F Miller; Christopher J Lindsell; Allen J Naftilan; John A McPherson; David J Maron; Douglas B Sawyer; Neal L Weintraub; Gregory J Fermann; Susan K Roll; Matthew Sperling; Alan B Storrow
Journal:  JACC Heart Fail       Date:  2015-10       Impact factor: 12.035

3.  Screening Characteristics of TIMI Score in Predicting Acute Coronary Syndrome Outcome; a Diagnostic Accuracy Study.

Authors:  Mostafa Alavi-Moghaddam; Saeed Safari; Hamideh Alavi-Moghaddam
Journal:  Emerg (Tehran)       Date:  2017-01-09

4.  Heart rate n-variability (HRnV) and its application to risk stratification of chest pain patients in the emergency department.

Authors:  Nan Liu; Dagang Guo; Zhi Xiong Koh; Andrew Fu Wah Ho; Feng Xie; Takashi Tagami; Jeffrey Tadashi Sakamoto; Pin Pin Pek; Bibhas Chakraborty; Swee Han Lim; Jack Wei Chieh Tan; Marcus Eng Hock Ong
Journal:  BMC Cardiovasc Disord       Date:  2020-04-10       Impact factor: 2.298

5.  Medical consumption compared for TIMI and HEART score in chest pain patients at the emergency department: a retrospective cost analysis.

Authors:  A Nieuwets; J M Poldervaart; J B Reitsma; S Buitendijk; A J Six; B E Backus; A W Hoes; P A Doevendans
Journal:  BMJ Open       Date:  2016-06-16       Impact factor: 2.692

6.  Prognostic utility of the combination of monocyte-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio in patients with NSTEMI after primary percutaneous coronary intervention: a retrospective cohort study.

Authors:  Zeyuan Fan; Yang Li; Hanhua Ji; Xinwen Jian
Journal:  BMJ Open       Date:  2018-10-18       Impact factor: 2.692

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.